Abstract The Center for Multiple Myeloma Nanotherapy (CMMN) Developmental Program will support Pilot and Auxiliary Projects that will be of critical importance to extend the impact of nanotherapeutics in treatment solutions in multiple myeloma and related bone cancer challenges. This Program will encourage new and innovative approaches to increase the clinical impact of nanotechnology in multiple myeloma by linking physicians, biologists, physical scientists, engineers, bioinformatics, and technologists for the purpose of improving diagnosis, prevention, and/or treatment. The support early discovery projects to explore high-risk development techniques that influence the success of anti-bone cancer technologies or address in particular the translational barriers to our vision. As a direct impact, the Developmental Program will lay the groundwork for supporting meritorious rapid advancements that can be integrated into the CMMN and as well as leveraging its assets and resources to acquire additional funding required to sustain these projects to achieve the translational goals of the CMMN. The Developmental Program is a significant component of the overall Center where the goal is to enhance CMMN’s capabilities and expand high-risk development and fundamental research into the barrier to influence translation of new cancer applications based on nanotechnology. The Aims are to: 1) Establish a formal process to solicit, review/evaluate, and award of Pilot and Auxiliary Projects to investigators and trainees intended to address the technology opportunities and translational barriers for nanotherapy success within the CMMN, 2) Monitor progress of selected project and actively develop new projects within the Center for the purpose of expanding the CMMN’s capabilities, and 3) To enhance the translation of CMMN technologies to the clinic through the education and support of investigator in the fundamentals entrepreneurial business formation and developmental research management.